Published in Nature on September 13, 2007
Syndromic surveillance: adapting innovations to developing settings. PLoS Med (2008) 2.38
A visual dashboard for moving health technologies from "lab to village". J Med Internet Res (2007) 1.10
How can developing countries harness biotechnology to improve health? BMC Public Health (2007) 1.06
Can incubators work in Africa? Acorn Technologies and the entrepreneur-centric model. BMC Int Health Hum Rights (2010) 0.89
Venture funding for science-based African health innovation. BMC Int Health Hum Rights (2010) 0.89
The road to commercialization in Africa: lessons from developing the sickle-cell drug Niprisan. BMC Int Health Hum Rights (2010) 0.85
A focused ethnographic study of Sri Lankan government field veterinarians' decision making about diagnostic laboratory submissions and perceptions of surveillance. PLoS One (2012) 0.85
Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Adv Drug Deliv Rev (2009) 0.84
Turning science into health solutions: KEMRI's challenges as Kenya's health product pathfinder. BMC Int Health Hum Rights (2010) 0.78
Developing global health technology standards: what can other industries teach us? Global Health (2013) 0.77
Sex, gender, and health biotechnology: points to consider. BMC Int Health Hum Rights (2009) 0.75
The role of community engagement in the adoption of new agricultural biotechnologies by farmers: the case of the Africa harvest tissue-culture banana in Kenya. BMC Biotechnol (2017) 0.75
The next generation. Nat Biotechnol (2009) 0.75
Grand challenges in global mental health. Nature (2011) 8.40
Grand challenges in global health: community engagement in research in developing countries. PLoS Med (2007) 4.75
Brazilian health biotech--fostering crosstalk between public and private sectors. Nat Biotechnol (2008) 2.57
India's health biotech sector at a crossroads. Nat Biotechnol (2007) 2.53
Ethics and SARS: lessons from Toronto. BMJ (2003) 2.39
Data safety and monitoring boards. N Engl J Med (2004) 2.09
Grand challenges in global health: the ethical, social and cultural program. PLoS Med (2007) 2.02
Chinese health biotech and the billion-patient market. Nat Biotechnol (2008) 2.00
Global health. Stagnant health technologies in Africa. Science (2010) 1.68
Grand challenges in global health: engaging civil society organizations in biomedical research in developing countries. PLoS Med (2007) 1.68
Nanotechnology and the developing world. PLoS Med (2005) 1.66
Small but tenacious: South Africa's health biotech sector. Nat Biotechnol (2009) 1.63
Moving from research ethics review to research ethics systems in low-income and middle-income countries. Lancet (2009) 1.62
Race and ancestry in biomedical research: exploring the challenges. Genome Med (2009) 1.55
Considerations for the use of human participants in vector biology research: a tool for investigators and regulators. Vector Borne Zoonotic Dis (2015) 1.52
Psychosocial effects of SARS on hospital staff: survey of a large tertiary care institution. CMAJ (2004) 1.51
Grand challenges in global health: ethical, social, and cultural issues based on key informant perspectives. PLoS Med (2007) 1.50
Aligning community engagement with traditional authority structures in global health research: a case study from northern Ghana. Am J Public Health (2011) 1.49
Needed: models of biotechnology intellectual property. Trends Biotechnol (2002) 1.48
Taking tissue seriously means taking communities seriously. BMC Med Ethics (2007) 1.47
Global health challenges: the need for an expanded discourse on bioethics. PLoS Med (2005) 1.46
The three main monotheistic religions and gm food technology: an overview of perspectives. BMC Int Health Hum Rights (2009) 1.45
Innovative health service delivery models in low and middle income countries - what can we learn from the private sector? Health Res Policy Syst (2010) 1.44
On pandemics and the duty to care: whose duty? who cares? BMC Med Ethics (2006) 1.43
Grand challenges: Integrating mental health care into the non-communicable disease agenda. PLoS Med (2013) 1.42
MedsCheck: an opportunity missed. CMAJ (2008) 1.40
Chaperone use during intimate examinations in primary care: postal survey of family physicians. BMC Fam Pract (2005) 1.39
Conclusions: promoting biotechnology innovation in developing countries. Nat Biotechnol (2004) 1.38
Implications of acquired environmental enteric dysfunction for growth and stunting in infants and children living in low- and middle-income countries. Food Nutr Bull (2013) 1.38
South Africa--blazing a trail for African biotechnology. Nat Biotechnol (2004) 1.34
Health care service utilization among the elderly: findings from the Study to Understand the Chronic Condition Experience of the Elderly and the Disabled (SUCCEED project). J Eval Clin Pract (2008) 1.33
Whole genome scanning: resolving clinical diagnosis and management amidst complex data. Pediatr Res (2009) 1.29
Science community: scientific diasporas. Science (2006) 1.29
State of academic knowledge on toxicity and biological fate of quantum dots. Toxicol Sci (2009) 1.23
The global alliance for chronic diseases. Science (2009) 1.23
Evidence for global health. CMAJ (2004) 1.23
What kind of evidence do we need to justify humanitarian medical aid? Lancet (2002) 1.20
Harnessing stem cells for health needs in India. Cell Stem Cell (2008) 1.19
Biotechnology and the UN's Millennium Development Goals. Nat Biotechnol (2003) 1.19
From pharmaco-therapy to pharmaco-prevention: trends in prescribing to older adults in Ontario, Canada, 1997-2006. BMC Fam Pract (2010) 1.19
Family physicians' attitudes toward education in research skills during residency: findings from a national mailed survey. Can Fam Physician (2008) 1.16
Trends in health services utilization, medication use, and health conditions among older adults: a 2-year retrospective chart review in a primary care practice. BMC Health Serv Res (2009) 1.15
Is evidence-based medicine overrated in family medicine?: Yes. Can Fam Physician (2013) 1.15
Regenerative medicine in Brazil: small but innovative. Regen Med (2010) 1.12
Genomics--a global public good? Lancet (2003) 1.11
Shared principles of ethics for infant and young child nutrition in the developing world. BMC Public Health (2010) 1.11
Introduction: promoting global health through biotechnology. Nat Biotechnol (2004) 1.10
Community engagement and the human infrastructure of global health research. BMC Med Ethics (2014) 1.10
Introducing new technologies: protecting subjects of surgical innovation and research. World J Surg (2003) 1.09
How can developing countries harness biotechnology to improve health? BMC Public Health (2007) 1.06
Cuba--innovation through synergy. Nat Biotechnol (2004) 1.06
"Harnessing genomics to improve health in India" - an executive course to support genomics policy. Health Res Policy Syst (2004) 1.06
Inhaled nitric oxide for the adjunctive therapy of severe malaria: protocol for a randomized controlled trial. Trials (2011) 1.06
Priority setting for orphan drugs: an international comparison. Health Policy (2010) 1.04
Judging the ethical merit of clinical trials: what criteria do research ethics board members use? IRB (1995) 1.04
The origins of a research community in the Majengo Observational Cohort Study, Nairobi, Kenya. BMC Public Health (2010) 1.04
Lessons on ethical decision making from the bioscience industry. PLoS Med (2006) 1.03
Genomics knowledge and equity: a global public goods perspective of the patent system. Bull World Health Organ (2004) 1.03
Patients' perspectives on taking warfarin: qualitative study in family practice. BMC Fam Pract (2004) 1.03
Case study: India's billion dollar biotech. Nat Biotechnol (2010) 1.02
The CNCDs and the NTDs: blurring the lines dividing noncommunicable and communicable chronic diseases. PLoS Negl Trop Dis (2008) 1.02
A population-based cohort study of ambulatory care service utilization among older adults. J Eval Clin Pract (2010) 1.01
Genomics, public health and developing countries: the case of the Mexican National Institute of Genomic Medicine (INMEGEN). Nat Rev Genet (2008) 1.01
Public engagement on global health challenges. BMC Public Health (2008) 1.01
Engaging communities in tuberculosis research. Lancet Infect Dis (2013) 1.01
Incentives for organ donation: proposed standards for an internationally acceptable system. Am J Transplant (2011) 0.99
Genomic medicine and developing countries: creating a room of their own. Nat Rev Genet (2008) 0.99
South-South entrepreneurial collaboration in health biotech. Nat Biotechnol (2010) 0.99
Indian biotechnology--rapidly evolving and industry led. Nat Biotechnol (2004) 0.98
A survey of South-North health biotech collaboration. Nat Biotechnol (2009) 0.96
The next steps for genomic medicine: challenges and opportunities for the developing world. Nat Rev Genet (2008) 0.96
Harnessing biodiversity: the Malagasy Institute of Applied Research (IMRA). BMC Int Health Hum Rights (2010) 0.96
A qualitative study of the duty to care in communicable disease outbreaks. Soc Sci Med (2007) 0.96
The assessment and treatment of a complex geriatric patient by an interprofessional primary care team. BMJ Case Rep (2011) 0.96
South Africa: from species cradle to genomic applications. Nat Rev Genet (2008) 0.96
Theatre as a public engagement tool for health-policy development. Health Policy (2005) 0.96
Science-based health innovation in sub-Saharan Africa. BMC Int Health Hum Rights (2010) 0.95
"Harnessing genomics to improve health in Africa" - an executive course to support genomics policy. Health Res Policy Syst (2005) 0.92
The scientific muscle of Brazil's health biotechnology. Nat Biotechnol (2004) 0.91
Health biotechnology in China--reawakening of a giant. Nat Biotechnol (2004) 0.91
Strengthening the role of genomics in global health. PLoS Med (2004) 0.91
A framework for research ethics review during public emergencies. CMAJ (2010) 0.91
Emergence of biopharmaceutical innovators in China, India, Brazil, and South Africa as global competitors and collaborators. Health Res Policy Syst (2012) 0.91
Cultivating regenerative medicine innovation in China. Regen Med (2010) 0.90
Harnessing genomics to improve health in the Eastern Mediterranean Region - an executive course in genomics policy. Health Res Policy Syst (2005) 0.90
South Korean biotechnology--a rising industrial and scientific powerhouse. Nat Biotechnol (2004) 0.90
Brokered dialogue: A new research method for controversial health and social issues. BMC Med Res Methodol (2012) 0.90
Can incubators work in Africa? Acorn Technologies and the entrepreneur-centric model. BMC Int Health Hum Rights (2010) 0.89
North-South partnerships--a study of Canadian firms. Nat Biotechnol (2007) 0.89
Venture funding for science-based African health innovation. BMC Int Health Hum Rights (2010) 0.89
Measuring change in health status of older adults at the population level: the transition probability model. BMC Health Serv Res (2010) 0.88